Literature DB >> 9306559

Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma.

S Murakami1, Y Uchida, S Takeno, T Noguchi, K Matsumoto, H Shimoda.   

Abstract

We examined the immunohistochemical expression of proliferating-cell nuclear antigen (PCNA) and p53 proteins in dysplasia and intramucosal carcinoma of the esophagus. Immunohistochemistry was performed with monoclonal antibodies directed against PCNA and p53. We used surgically resected specimens from 29 patients who had a total of 55 lesions of severe dysplasia (n = 16), intraepithelial carcinoma (n = 21), and mucosal carcinoma (n = 18). The mean PCNA index with immunoreactivity for p53 was 48.9 +/- 6.5 in areas of severe dysplasia (n = 7), 58.2 +/- 7.3 in areas of intraepithelial carcinoma (n = 10), and 71.4 +/- 9.3 in the invasive areas of mucosal carcinoma (n = 10). The mean PCNA index without immunoreactivity for p53 was 41.2 +/- 5.5 in areas of severe dysplasia (n = 9), 48.0 +/- 7.4 in areas of intraepithelial carcinoma (n = 11), and 63.7 +/- 9.1 in invasive areas of mucosal carcinoma (n = 8). The PCNA indices of the areas of severe dysplasia with immunoreactivity for p53 were significantly lower than those of intraepithelial carcinoma and mucosal carcinoma with immunoreactivity for p53. Similarly, the PCNA indices of severe dysplasia without immunoreactivity for p53 were significantly lower than those of intraepithelial carcinoma and mucosal carcinoma without immunoreactivity for p53. These results thus suggest that severe dysplasia has a lower proliferative potential than carcinoma and may therefore represent a precancerous lesion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306559     DOI: 10.1007/BF02388213

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.540


  19 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.

Authors:  A A Sahin; J Ro; J Y Ro; M B Blick; A K el-Naggar; N G Ordonez; H A Fritsche; T L Smith; G N Hortobagyi; A G Ayala
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

3.  Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA analysis.

Authors:  H Matsuura; K Sugimachi; H Ueo; H Kuwano; Y Koga; T Okamura
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

4.  SV40-53K antigen: a possible role for 53K in normal cells.

Authors:  J Milner; S Milner
Journal:  Virology       Date:  1981-07-30       Impact factor: 3.616

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis.

Authors:  Y Morisaki; S Shima; Y Yoshizumi; Y Sugiura; S Tanaka; S Tamai
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma.

Authors:  T W Rice; J R Goldblum; G W Falk; R R Tubbs; T J Kirby; G Casey
Journal:  J Thorac Cardiovasc Surg       Date:  1994-12       Impact factor: 5.209

9.  Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry.

Authors:  G D Wilson; N J McNally; S Dische; M I Saunders; C Des Rochers; A A Lewis; M H Bennett
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Prognostic significance of modal DNA value and other factors in malignant tumours, based on 1465 cases.

Authors:  N B Atkin; R Kay
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.